Equities analysts forecast that Cerner Co. (NASDAQ:CERN) will post $1.34 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have provided estimates for Cerner’s earnings, with estimates ranging from $1.33 billion to $1.35 billion. Cerner posted sales of $1.26 billion during the same quarter last year, which would indicate a positive year over year growth rate of 6.3%. The company is expected to report its next quarterly earnings report on Thursday, April 26th.

According to Zacks, analysts expect that Cerner will report full year sales of $1.34 billion for the current year, with estimates ranging from $5.49 billion to $5.61 billion. For the next fiscal year, analysts anticipate that the business will post sales of $6.02 billion per share, with estimates ranging from $5.88 billion to $6.16 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Cerner.

Cerner (NASDAQ:CERN) last released its earnings results on Tuesday, February 6th. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.03). Cerner had a return on equity of 16.82% and a net margin of 16.86%. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same period last year, the firm posted $0.61 EPS. Cerner’s quarterly revenue was up 4.5% compared to the same quarter last year.

Several research firms have recently commented on CERN. Zacks Investment Research downgraded shares of Cerner from a “buy” rating to a “hold” rating in a report on Thursday. Royal Bank of Canada reissued a “buy” rating and issued a $76.00 target price on shares of Cerner in a report on Wednesday. Cantor Fitzgerald lowered their target price on shares of Cerner from $83.00 to $80.00 and set an “overweight” rating on the stock in a report on Wednesday. Robert W. Baird lowered their target price on shares of Cerner from $80.00 to $75.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Canaccord Genuity reissued a “buy” rating on shares of Cerner in a report on Wednesday. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the stock. Cerner has a consensus rating of “Hold” and a consensus target price of $67.05.

In related news, VP Michael R. Battaglioli sold 4,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $69.89, for a total transaction of $279,560.00. Following the sale, the vice president now owns 4,000 shares of the company’s stock, valued at $279,560. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, President Zane M. Burke sold 50,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $70.00, for a total transaction of $3,500,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 784,000 shares of company stock worth $51,926,960. 13.11% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Baird Financial Group Inc. raised its stake in shares of Cerner by 38.2% in the fourth quarter. Baird Financial Group Inc. now owns 14,715 shares of the company’s stock valued at $992,000 after acquiring an additional 4,064 shares during the period. Norinchukin Bank The raised its stake in shares of Cerner by 7.7% in the fourth quarter. Norinchukin Bank The now owns 25,249 shares of the company’s stock valued at $1,702,000 after acquiring an additional 1,804 shares during the period. FDx Advisors Inc. raised its stake in shares of Cerner by 15.4% in the fourth quarter. FDx Advisors Inc. now owns 22,500 shares of the company’s stock valued at $1,516,000 after acquiring an additional 3,005 shares during the period. ARP Americas LP raised its stake in shares of Cerner by 128.9% in the fourth quarter. ARP Americas LP now owns 6,680 shares of the company’s stock valued at $450,000 after acquiring an additional 3,762 shares during the period. Finally, Synovus Financial Corp raised its stake in shares of Cerner by 2.8% in the fourth quarter. Synovus Financial Corp now owns 46,306 shares of the company’s stock valued at $3,114,000 after acquiring an additional 1,241 shares during the period. 81.99% of the stock is currently owned by institutional investors.

Cerner (NASDAQ:CERN) traded up $0.09 during mid-day trading on Thursday, hitting $61.31. 3,400,939 shares of the stock traded hands, compared to its average volume of 2,440,000. Cerner has a 1 year low of $51.26 and a 1 year high of $73.86. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.01 and a quick ratio of 2.75. The stock has a market capitalization of $20,380.00, a P/E ratio of 23.86, a PEG ratio of 1.80 and a beta of 0.90.

TRADEMARK VIOLATION WARNING: “Analysts Anticipate Cerner Co. (CERN) Will Post Quarterly Sales of $1.34 Billion” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://theolympiareport.com/2018/02/11/analysts-anticipate-cerner-co-cern-will-post-quarterly-sales-of-1-34-billion.html.

Cerner Company Profile

Cerner Corporation (Cerner) is a supplier of healthcare information technology (HCIT). The Company offers a range of intelligent solutions and services that support the clinical, financial and operational needs of organizations of all sizes. The Company’s segments include Domestic and Global. The Domestic segment includes revenue contributions and expenditures associated with business activity in the United States.

Get a free copy of the Zacks research report on Cerner (CERN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cerner Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerner and related companies with MarketBeat.com's FREE daily email newsletter.